
Agilent Technologies, Inc.
ANYSEHealthcareMedical - Diagnostics & Research
Regular session
$152.93
−$6.07 · -3.82%
A company overview
Regular session · ET · Market data may be delayed.
GoAI snapshot
AI-powered factor overview
GoAI score
Hold
Wait — insufficient conviction to act
Valuation
86
Deep Value
Momentum
48
Neutral
Sentiment
61
Bullish
Risk resilience
51
Elevated Risk
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
AI-generated, informational only, and not investment advice.
Company profile
Company websiteAgilent Technologies, Inc. delivers specialized, application-focused technologies and services to the global life sciences, diagnostics, and applied chemistry industries. Its Life Sciences and Applied Markets segment provides a comprehensive portfolio of analytical instrumentation. This includes liquid chromatography (LC) and gas chromatography (GC) systems, often integrated with mass spectrometry (MS) for advanced analysis (LC-MS, GC-MS). They also offer inductively coupled plasma mass spectrometry (ICP-MS), atomic absorption (AA), microwave plasma-atomic emission spectrometry (MP-AES), and inductively coupled plasma optical emission spectrometry (ICP-OES) instruments, alongside Raman spectroscopy for material characterization. Beyond spectroscopy, the segment supplies cell analysis solutions such as plate-based assays, flow cytometers, real-time cell analyzers, imaging systems, and microplate readers. Complementing these are various laboratory software, information management platforms, data analytics tools, automated and robotic lab systems, dissolution testing equipment, vacuum technology, and general measurement solutions. The Diagnostics and Genomics division offers cutting-edge tools for genetic and diagnostic research. These encompass arrays designed for DNA mutation detection, genotyping, gene copy number determination, identification of gene rearrangements, DNA methylation profiling, and gene expression analysis. This segment also provides target enrichment solutions for next-generation sequencing, along with software for genetic data management and interpretation. Furthermore, it synthesizes custom oligonucleotides. Other significant offerings include immunohistochemistry (IHC), in situ hybridization (ISH), hematoxylin and eosin (H&E) staining, and specialized staining solutions. The division also supplies consumables and software essential for quality control analysis of nucleic acid samples, as well as reagents for turbidimetry and flow cytometry applications. A key area of development for this segment is liquid-based pharmacodiagnostics. Agilent CrossLab, the third segment, focuses on providing essential laboratory consumables and services. Its product range features GC and LC columns, products for sample preparation, custom chemical formulations, and various supplies for laboratory instruments. Complementary services include expert support for startup, ongoing operations, training, compliance, Software-as-a-Service (SaaS) offerings, asset management, and professional consultation. The company's products reach customers through a diverse sales network, including direct sales teams, distributors, resellers, manufacturer's representatives, and its e-commerce platforms. Agilent Technologies, Inc. was established in 1999 and maintains its corporate headquarters in Santa Clara, California.
- Industry
- Medical - Diagnostics & Research
- Sector
- Healthcare
- Headquarters
- US
- CEO
- Padraig McDonnell
- Listed since
- Nov 18, 1999
- Employees
- 18,000
Market position
Day range
Current $152.93
52-week range
Current $152.93
- Open
- $156.56
- Previous close
- $159
- Volume
- 1.61M
- 0.72× average
- Average volume
- 2.24M
- Average daily volume
- Market cap
- 43.19B USD
- Beta
- 1.23
- Market reference 1
- 50-day average
- $137.52
- +11.21% above average
- 200-day average
- $131.3
- +16.47% above average
Financials
Financial snapshot
Latest / TTMValuation & yield
- Enterprise value
- 42.98B USD
- EV / EBITDA
- 23.43×
- Earnings yield
- 3.15%
- Free cash flow yield
- 2.78%
Profitability & efficiency
- Return on equity
- 19.33%
- Return on assets
- 10.24%
- Return on invested capital
- 12.57%
Financial health
- Current ratio
- 1.96×
Financial statements
Margin trends
Profitability as a percentage of reported revenue.
Income trends
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 6.95B USD | 6.51B USD | 6.83B USD | 6.85B USD | 6.32B USD |
| Cost of goods sold | 3.31B USD | 2.98B USD | 3.37B USD | 3.13B USD | 2.91B USD |
| Gross profit | 3.64B USD | 3.54B USD | 3.47B USD | 3.72B USD | 3.41B USD |
| Research and development | 455M USD | 479M USD | 481M USD | 467M USD | 441M USD |
| Selling, general, and administrative | 1.71B USD | 1.52B USD | 1.63B USD | 1.64B USD | 1.62B USD |
| Operating expenses | 2.16B USD | 2.05B USD | 2.12B USD | 2.1B USD | 2.06B USD |
| Interest income | 62M USD | 80M USD | 51M USD | 9M USD | 2M USD |
| Interest expense | 112M USD | 96M USD | 95M USD | 84M USD | 81M USD |
| Depreciation and amortization | 288M USD | 257M USD | 271M USD | 317M USD | 321M USD |
| Operating income | 1.48B USD | 1.49B USD | 1.35B USD | 1.62B USD | 1.35B USD |
| Net income | 1.3B USD | 1.29B USD | 1.24B USD | 1.25B USD | 1.21B USD |
Company facts updated Aug 24, 2026.
Earnings
- EPS beat rate
- 82%
- 9 beats, 1 miss, 1 met estimate
- Average EPS surprise
- +2.83%
- 11 comparable reports
- Latest EPS result
- 1.49
- Estimate 1.41 · Beat by 5.67%
EPS: actual versus estimate
Recent quarterly results
Revenue: actual versus estimate
Recent quarterly results
Corporate actions
Annual dividends per share
Cash distributions grouped by calendar year; partial years are marked.
$0.956
2024 complete year+42.3% since 2019
2026 partial: $0.765
$0.672
2,019
$0.776
2,021
$1.065
2,022
$0.911
2,023
$0.956
2,024
$0.765
2,026*
* Partial calendar year in the available dividend history.
Corporate action history
| Action | Ex-dividend date | Details | Record date | Payment date |
|---|---|---|---|---|
Dividend | Jun 30, 2026 | $0.255Quarterly | Jun 30, 2026 | Jul 22, 2026 |
Dividend | Mar 31, 2026 | $0.255Irregular | Mar 31, 2026 | Apr 22, 2026 |
Dividend | Jan 6, 2026 | $0.255Quarterly | Jan 6, 2026 | Jan 28, 2026 |
Dividend | Sep 30, 2025 | $0.248Quarterly | Sep 30, 2025 | Oct 22, 2025 |
Dividend | Jul 1, 2025 | $0.248Quarterly | Jul 1, 2025 | Jul 23, 2025 |
Dividend | Apr 1, 2025 | $0.248Quarterly | Apr 1, 2025 | Apr 23, 2025 |
Ex-dividend Jun 30, 2026
$0.255
Quarterly
Record Jun 30, 2026 · Payment Jul 22, 2026
Ex-dividend Mar 31, 2026
$0.255
Irregular
Record Mar 31, 2026 · Payment Apr 22, 2026
Ex-dividend Jan 6, 2026
$0.255
Quarterly
Record Jan 6, 2026 · Payment Jan 28, 2026
Ex-dividend Sep 30, 2025
$0.248
Quarterly
Record Sep 30, 2025 · Payment Oct 22, 2025
Ex-dividend Jul 1, 2025
$0.248
Quarterly
Record Jul 1, 2025 · Payment Jul 23, 2025
Ex-dividend Apr 1, 2025
$0.248
Quarterly
Record Apr 1, 2025 · Payment Apr 23, 2025
ETFs holding A
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI1.24B0.05%2.3T USD0.03%$376.96-0.34%
Vanguard S&P 500 ETFVOO1.03B0.06%1.7T USD0.03%$701.68-0.29%
Vanguard Morningstar Mid-Cap ETFVO845.14M0.37%224.7B USD0.03%$82.625-0.42%
iShares Core S&P 500 ETFIVV600.58M0.07%891.84B USD0.03%$766.98-0.30%
State Street SPDR S&P 500 ETFSPY556.44M0.07%817.87B USD0.09%$763.39-0.30%
Vanguard Morningstar Value ETFVTV371.96M0.14%256.5B USD0.03%$226.19-0.09%
State Street Health Care Select Sector SPDR ETFXLV318.94M0.71%44.76B USD0.08%$174.37-0.15%
Vanguard Morningstar Mid-Cap Growth ETFVOT298.63M0.89%33.5B USD0.05%$302.05-1.12%
Vanguard Morningstar Total Stock Market ETFVTI- Market value
- 1.24B
- Weight
- 0.05%
- AUM
- 2.3T USD
- Expense ratio
- 0.03%
- Price / 1D
- $376.96-0.34%
Vanguard S&P 500 ETFVOO- Market value
- 1.03B
- Weight
- 0.06%
- AUM
- 1.7T USD
- Expense ratio
- 0.03%
- Price / 1D
- $701.68-0.29%
Vanguard Morningstar Mid-Cap ETFVO- Market value
- 845.14M
- Weight
- 0.37%
- AUM
- 224.7B USD
- Expense ratio
- 0.03%
- Price / 1D
- $82.625-0.42%
iShares Core S&P 500 ETFIVV- Market value
- 600.58M
- Weight
- 0.07%
- AUM
- 891.84B USD
- Expense ratio
- 0.03%
- Price / 1D
- $766.98-0.30%
State Street SPDR S&P 500 ETFSPY- Market value
- 556.44M
- Weight
- 0.07%
- AUM
- 817.87B USD
- Expense ratio
- 0.09%
- Price / 1D
- $763.39-0.30%
Vanguard Morningstar Value ETFVTV- Market value
- 371.96M
- Weight
- 0.14%
- AUM
- 256.5B USD
- Expense ratio
- 0.03%
- Price / 1D
- $226.19-0.09%
State Street Health Care Select Sector SPDR ETFXLV- Market value
- 318.94M
- Weight
- 0.71%
- AUM
- 44.76B USD
- Expense ratio
- 0.08%
- Price / 1D
- $174.37-0.15%
Vanguard Morningstar Mid-Cap Growth ETFVOT- Market value
- 298.63M
- Weight
- 0.89%
- AUM
- 33.5B USD
- Expense ratio
- 0.05%
- Price / 1D
- $302.05-1.12%
Continue in GoAI
Research Aresearch.disclaimer